Season 9, Episode 3 - Hepatitis C, Re-infection or Failure of Treatment in People Engaging in High Risk Practices – Do These Labels Matter in 2025?

What do we call it when someone with high-risk practices becomes viraemic again after treatment? In this episode, experts discuss the challenges of managing Hepatitis C in people who inject drugs (PWID) and other high-risk groups. Topics include SVR confirmation rates, DAA prescribing practices, acute vs. chronic infection, and real-world reinfection data. Are traditional labels still meaningful or do we need new frameworks for 2025?

Faculty: Ahmed Elsharkawy (Moderator), Ashley Brown (Faculty), Tatyana Kushner (Faculty), Sabela Lens (Faculty)